medigraphic.com
ISSN 1561-2996 (Electronic)
ISSN 0864-0289 (Print)

2020, Number 1

<< Back Next >>

Rev Cubana Hematol Inmunol Hemoter 2020; 36 (1)

Characterization of leukemias in Cuban children (2006-2015)

Machín GSA, Leblanch FCC, García CMB, Escalona VY, Álvarez MI, Plá TMJ, Valdés SC

Language: English
References: 33
Page: 1-15
PDF size: 489.38 Kb.


ABSTRACT

Introduction: Leukemia is the most frequent cancer in pediatric ages. Acute lymphoid leukemia (ALL) accounts for 23% of cancer diagnoses in children at ages under 15 years and 75% of all leukemias. More than 90% of childhood acute myeloid leukemias (AML) are acute and the rest are chronic.
Objective: To characterize acute leukemias in pediatric age in Cuba.
Methods: Descriptive, longitudinal and retrospective study. The sample was 799 children from all over Cuba, who were treated in any of the country‘s seven pediatric hospitals accredited for the treatment of acute leukemias, between January 2006 and December 2015. As a summary measure for the quantitative variables, the mean and standard deviation were used. For all qualitative variables, the percentages of each group were calculated.
Results: Incidence rates were 2.9 per 100,000 children. 95% were acute leukemias (70.6% lymphoid), with 34.9% corresponding to promyelocytic leukemia (PML) in AML. The male sex predominated and the average diagnosis age was 7.1 years. The percentage of complete remission in ALL was 91%, and 66.7% in AML. The frequency of disease relapse was 25.1% in ALL, 13.7% in LPM, and 45% in other myeloid leukemias. Overall and event-free survival was 89% and 63% in children with ALL, 64% and 62% in LPM, 38% and 36% in non-promyelocytic AML, respectively.
Conclusions: Frequency and age distribution of leukemias in Cuban children are similar to that described worldwide. The results of treatment in acute leukemias in general can be considered as good.


REFERENCES

  1. Steliarova-Foucher E, Fidler MM, Colombet M, Lacour B, Kaatsch P, Piñeros M, et al. Changing geographical patterns and trends in cancer incidence in children and adolescents in Europe, 1991-2010 (Automated Childhood Cancer Information System): a populationbased study. Lancet Oncol. 2018 Sep;19(9):1159-1169. doi: 10.1016/S14702045(18)30423-6.

  2. Alejandro Gutierrez, Lewis B. Silverman. Acute Lymphoblastic Leukemia. In: Nathan and Oski's Hematology and Oncology of Infancy and Childhood, 8th ed. Philadelphia: Elsevier Saunders; 2015. p. 1535.

  3. Izquierdo U, Casas V, Bonalde Y. Incidencia y prevalencia de las leucemias. Pronósticos a largo plazo a nivel mundial. Rev. Oncología. Chile 2015;86(21):124-6.

  4. Steliarova-Foucher E, Colombet M, Ries LAG, Moreno F, Dolya A, Bray F, et al. International incidence of childhood cancer, 2001-10: a population-based registry study. Lancet Oncol. 2017 Jun;18(6):719-31. doi: 10.1016/S1470-2045(17)30186-9

  5. Equipo de redactores y equipo de editores médicos de la Sociedad Americana contra el Cáncer. Estadísticas importantes sobre la leucemia en niños. 2019 Feb [acceso 02/05/2019]. Disponible en: https://www.cancer.org/es/cancer/leucemia-en-ninos/acerca/estadisticasclave.html

  6. Bonaventure A, Harewood R, Stiller CA, Gatta G, Clavel J, Stefan DC, et al. Worldwide comparison of survival from childhood leukaemia for 1995-2009, by subtype, age, and sex (CONCORD-2): a population-based study of individual data for 89 828 children from 198 registries in 53 countries. Lancet Haematol. 2017 May;4(5):e202-e217.

  7. Richard AL. Acute Lymphoblastic leukemia: in Williams Hematology. 9th Ed. New York: McGraw-Hill Education; 2017. p. 1504.

  8. Luque J, Condes O, Pinto I. Factores de riesgo maternos y ambientales de los pacientes pediátricos con diagnóstico de leucemia. Rev Pediatría Bolivia 2016;17(2):89-92

  9. Bassan R, Hoelzer D. Modern Therapy of Acute Lymphoblastic Leukemia. J Clin Oncol. 2011 Feb 10;29(5):532-43. doi: 10.1200/JCO.2010.30.1382

  10. Kato M, Manabe A. Treatment and biology of pediatric acute lymphoblastic leukemia. Pediatr Int. 2018 Jan;60(1):4-12.

  11. Juliusson G, Hough R. Leukemia. Prog Tumor Res. 2016;43:87-100. doi: 10.1159/000447076

  12. Vrooman LM, Silverman LB. Treatment of Childhood Acute Lymphoblastic Leukemia: Prognostic Factors and Clinical Advances. Curr Hematol Malig Rep. 2016 Oct;11(5):385- 94.

  13. Winestone LE, Aplenc R. Disparities in Survival and Health Outcomes in Childhood Leukemia. Curr Hematol Malig Rep. 2019 Jun;14(3):179-186. doi: 10.1007/s11899-01900515-x

  14. Drachtman RA, Masterson M, Shenkerman A, Vijayanathan V, Cole PD. Long-term outcomes for children with acute lymphoblastic leukemia (ALL) treated on The Cancer Institute of New Jersey ALL trial (CINJALL). Leuk Lymphoma. 2016 Oct;57(10):2275-80.

  15. Stary J, Zimmermann M, Campbell M, Castillo L, Dibar E, Donska S. Intensive chemotherapy for childhood acute lymphoblastic leukemia: results of the randomized intercontinental trial ALL IC-BFM 2002 J Clin Oncol. 2014 Jan 20;32(3):174-84.

  16. González A, Arencibia A, Machín S, Menéndez A, Gutiérrez AI, Nordet I, et al. Protocolo ALLIC-BFM 2002 en el Instituto de Hematología e Inmunología: experiencia de 10 años. Rev Cub Hematol Inmunol Hemoter. 2015 [acceso 30/05/2019];32(1):[aprox. 0 p.]. Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/311

  17. Menéndez A, González A, Svarch E, Rosell E, Campo M, Arencibia A, et al. Resultados del tratamiento de la leucemia mieloide aguda del niño en Cuba. Rev Cub Hematol Inmunol Hemoter. 2013 [acceso 19/08/2019];29(2):[aprox. 0 p.]. Disponible en: http://www.revhematologia.sld.cu/index.php/hih/article/view/34

  18. National Cancer Institute. Surveillance, Epidemiology, and End Results Program. 2019 Abril [acceso 15/06/2019]. Disponible en: https://seer.cancer.gov/explorer/application.php?site=1&data_type=1&graph_type=2&co mpareBy=age_range&chk_sex_1=1&chk_sex_3=3&chk_sex_2=2&chk_race_1=1&chk_a ge_range_1=1&chk_age_range_15=15&chk_data_type_1=1&advopt_precision=1&advop t_display=2&showDataFor=sex_3_and_race_1_and_data_type_1

  19. Musselman JR, Spector LG, Krailo MD, Reaman GH, Linabery AM, et al. The Children’s Oncology Group Childhood Cancer Research Network (CCRN). Case Catchment in the United States. Cancer. 2014 Oct;120(19):3007-15. doi: 10.1002/cncr.28813

  20. Niemeyer CM, Arico M, Basso G, Biondi A, Cantu Rajnoldi A, Creutzig U, et al. Chronic myelomonocytic leukemia in childhood: a retrospective analysis of 110 cases. European Working Group on Myelodysplastic Syndromes in Childhood (EWOG-MDS) Blood. 1997 May 15;89(10):3534-43.

  21. Ishihara H, Ohno Y, Fujii M, Hara J, Soda M. Epidemiological analysis of childhood cancer in Japan based on population-based cancer registries, 1993-2009. Jpn J Clin Oncol. 2017 Mar;17:1-4.

  22. Thuler LCS, Pombo-de-Oliveira MS. Acute promyelocytic leukaemia is highly frequent among acute myeloid leukaemias in Brazil: a hospital-based cancer registry study from 2001 to 2012. Ann Hematol. 2017 Mar;96(3):355-62.

  23. Giddings BM, Whitehead TP, Metayer C, Miller MD. Childhood leukemia incidence in California: High and rising in the Hispanic population. Cancer. 2016 Sep;122(18):2867-75.

  24. Informe final. Censo de Población y Viviendas 2012 - Resumen adelantado - Resultados definitivos de indicadores seleccionados en Cuba, provincias y municipios. Población total por grandes grupos de edades, centenarios e indicadores de envejecimiento según provincias y municipios. p.61. [acceso 15/07/2019]. Disponible en: http://www.one.cu/publicaciones/cepde/cpv2012/20131107resumenadelantado/Tablas/3.p df

  25. Pieters R, de Groot-Kruseman H, Van der Velden V, Fiocco M, van den Berg H, de Bont E, et al. Successful Therapy Reduction and Intensification for Childhood Acute Lymphoblastic Leukemia Based on Minimal Residual Disease Monitoring: Study ALL10 from the Dutch Childhood Oncology Group. J Clin Oncol. 2016 Aug 1;34(22):2591-601.

  26. Jastaniah W, Al Ghemlas I, Al Daama S, Ballourah W, Bayoumy M, Al-Anzi F, et al. Clinical characteristics and outcome of childhood de novo acute myeloid leukemia in Saudi Arabia: A multicenter SAPHOS leukemia group study. Leuk Res. 2016 Oct;49:66-72.

  27. Taga T, Tomizawa D, Takahashi H, Adachi S. Acute myeloid leukemia in children: Current status and future directions. Pediatr Int. 2016 Feb;58(2):71-80. doi: 10.1111/ped.12865

  28. Antillón FG, Blanco JG, Valverde PD, Castellanos M, Garrido CP, Girón V, et al. The treatment of childhood acute lymphoblastic leukemia in Guatemala: Biologic features, treatment hurdles, and results. Cancer. 2017 Feb 1;123(3):436-48.

  29. Shen S, Cai J, Chen J, Xue H, Pan C, Gao Y, et al. Long-term results of the risk-stratified treatment of childhood acute lymphoblastic leukemia in China. Hematol Oncol. 2018 Oct;36(4):679-88.

  30. Seksarn P, Wiangnon S, Veerakul G, Chotsampancharoen T, Kanjanapongkul S, Chainansamit SO. Outcome of Childhood Acute Lymphoblastic Leukemia Treated Using the Thai National Protocols. Asian Pac J Cancer Prev. 2015;16(11):4609-14.

  31. Lengfelder E, Lo-Coco F, Ades L, Montesinos P, Grimwade D, Kishore B, et al. Arsenic trioxide-based therapy of relapsed acute promyelocytic leukemia: registry results from the European Leukemia Net. Leukemia. 2015 May;29(5):1084-91.

  32. Abrahão R, Ribeiro RC, Medeiros BC, Keogh RH, Keegan TH. Disparities in early death and survival in children, adolescents, and young adults with acute promyelocytic leukemia in California. Cancer. 2015 Nov 15;121(22):3990-7.

  33. Alexander TB, Wang L, Inaba H, Triplett BM, Pounds S, Ribeiro RC, et al. Decreased relapsed rate and treatment-related mortality contribute to improved outcomes for pediatric acute myeloid leukemia in successive clinical trials. Cancer. 2017 Oct;123(19):3791-8. doi: 10.1002/cncr.30791.




2020     |     www.medigraphic.com